Personalis to Participate at Upcoming Investor Conferences
Get Alerts PSNL Hot Sheet
Join SI Premium – FREE
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences:
-
Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Thursday, September 5, 2024
Presentation Time: 4:50 pm Eastern Time
Location: Marriott Marquis in New York
-
Lake Street 8th Annual Best Ideas Growth (BIG) Conference
Date: Thursday, September 12, 2024
Location: Yale Club in New York
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822337911/en/
Investors:
Caroline Corner
[email protected]
415-202-5678
Media:
[email protected]
Source: Personalis, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
- Crypto News Today: Tether Leads $15M AI Payments Round as Remittix Earn Prepares Aave, Morpho and Fluid Pools
- ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Morgan Stanley, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share